Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

Celgene Corporation announced that updated results of a phase II, multi-center, randomized, double-blind, placebo-controlled, three-arm study of apremilast in adult patients with psoriatic arthritis (CC-10004-PSA-001) were presented today at the American College of Rheumatology (ACR) 2009 annual meeting in Philadelphia, PA.

20 Oct 2009

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

UCB today announced data that showed rapid and sustained improvements in ACR20, physical function, pain and fatigue of rheumatoid arthritis (RA) as early as the first week, and inhibition of progression of structural joint damage (seen at week 24) following treatment with Cimzia (certolizumab pegol), together with methotrexate (MTX), was sustained up to 100 weeks.

19 Oct 2009

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

New long-term data from two pivotal, Phase 3 clinical trials showed that patients with active rheumatoid arthritis (RA) receiving SIMPONI(TM) (golimumab) every four weeks achieved sustained improvements in signs and symptoms and physical function response through one year. These new data were presented today at the 2009 American College of Rheumatology (ACR) Annual Scientific Meeting.

19 Oct 2009

Amgen receives Complete Response Letter for the Biologic License Applications for Prolia from FDA

Amgen Inc. today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Applications (BLA) for Prolia(TM) (denosumab) in the treatment and prevention of postmenopausal osteoporosis.

19 Oct 2009

Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis

Trubion Pharmaceuticals, Inc. today announced favorable safety and efficacy data following administration of a second course (R2) of re-treatment with 800 mg of TRU-015 for rheumatoid arthritis (RA). These data are the latest results from the ongoing open-label re-treatment portion of the Phase 2b (15002) RA study of TRU-015. Pfizer Inc. and Trubion are collaborating on the development of TRU-015 for the treatment of autoimmune and inflammatory diseases, including RA.

19 Oct 2009

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Schering-Plough announced that data on boceprevir, an investigational hepatitis C virus (HCV) protease inhibitor, will be reported in an oral presentation at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting in Boston, Oct. 30-Nov. 3.

19 Oct 2009

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Genentech, Inc., a wholly-owned member of the Roche Group, today announced two-year results from a Phase III study, which showed that people with rheumatoid arthritis (RA) who received either a 4 mg/kg or 8 mg/kg dose of ACTEMRA® (tocilizumab), in combination with methotrexate, had no progression of joint damage, (75 and 83 percent, respectively, as assessed by radiograph) compared with people who received methotrexate alone (66 percent).

19 Oct 2009

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Proteolix, Inc. today announced that data from preclinical studies of carfilzomib and PR-957 will be presented at the 2009 ACR/ARHP Annual Scientific Meeting on October 16 - 21 in Philadelphia, PA.

19 Oct 2009

Discovery may yield better understanding of protective gut-dwelling bacteria

Medical researchers have long suspected that obscure bacteria living within the intestinal tract may help keep the human immune system in balance. An international collaboration co-led by scientists at NYU Langone Medical Center has now identified a bizarre-looking microbial species that can single-handedly spur the production of specialized immune cells in mice.

19 Oct 2009

Rituxan's sBLA receives a Complete Response from the FDA

Genentech, Inc. a wholly-owned member of the Roche Group, and Biogen Idec announced today that the companies received a Complete Response from the U.S. Food and Drug Administration (FDA) for a supplemental Biologics License Application (sBLA) for Rituxan (rituximab) plus methotrexate (MTX) in patients with moderately-to-severely active rheumatoid arthritis (RA) who no longer respond to treatment with a disease modifying antirheumatic drug (DMARD), including MTX.

19 Oct 2009

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

Biogen Idec and Biovitrum AB (STO: BVT) today announced that they plan to advance the companies’ long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in hemophilia B patients.

19 Oct 2009

PHARMACIA & UPJOHN COMPANY to pay the largest criminal fine ever imposed in the U.S.

PHARMACIA & UPJOHN COMPANY, INC., a subsidiary of Pfizer Inc. ("Pfizer") today was sentenced today in federal court for a felony violation of the Food, Drug & Cosmetic Act, for misbranding the drug, Bextra, with the intent to defraud or mislead.

19 Oct 2009

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Persistent inflammation and the activation of the immune system is the key pathological mechanism affecting many long-term conditions, such as rheumatoid arthritis, psoriasis, ulcerative colitis, and Crohn's disease and is the predominant mechanism underlying organ transplant rejection.

19 Oct 2009

Rituxan drug effective for treating ANCA-associated vasculitis

Researchers have identified that Rituxan, a drug previously approved for the treatment of non-Hodgkin's B cell lymphoma and rheumatoid arthritis, can treat severe ANCA-associated vasculitis as effectively as cyclophosphamide, the current standard therapy.

19 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

National Vaccine Information Center to launch a research fundraising campaign

At the Oct. 2-4, 2009 Fourth International Public Conference on Vaccination sponsored by the non-profit National Vaccine Information Center in Reston, VA, 700 citizens from 44 states and 11 nations raised more than $100,000 to launch an international scientific research fundraising campaign to investigate health differences between vaccinated and unvaccinated children and identify those at risk for suffering vaccine injury.

14 Oct 2009

Decision Resources: Rheumatoid arthritis drug market in India to grow up to $672 million in 2013

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in India will more than double by 2013, growing from $296 million in 2008 to $672 million in 2013.

14 Oct 2009

Johnson & Johnson announces financial results for the third quarter of 2009

Johnson & Johnson today announced sales of $15.1 billion for the third quarter of 2009, a decrease of 5.3% as compared to the third quarter of 2008. Operational results declined 2.8% and the negative impact of currency was 2.5%. Domestic sales declined 8.1%, while international sales declined 2.5%, reflecting operational growth of 2.4% and a negative currency impact of 4.9%.

13 Oct 2009

Pharmaceuticals to provide safe needle collection and disposal programs for patients

It is illegal in the state of California to unsafely dispose of "sharps" (medical waste such as needles and syringes) in the home, and thanks to California State Senator Joe Simitian's Senate Bill 486, and contributors from his annual "There Oughta Be A Law" contest, 1 million Californians will not be breaking the law anymore (see http://www.ciwmb.ca.gov/hhw/sharps/).

13 Oct 2009

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Nektar Therapeutics presented topline data today from its Phase 2 clinical trial of oral NKTR-118 at the American Academy of Pain Management's (AAPM) 20th Annual Clinical Meeting in Phoenix, Arizona.

12 Oct 2009

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Celgene Corporation updates on Phase II study evaluating apremilast in psoriatic arthritis patients

UCB reports on the outcome of Cimzia and MTX treatment for rheumatoid arthritis

New data on Phase 3 SIMPONI clinical trials for rheumatoid arthritis

Amgen receives Complete Response Letter for the Biologic License Applications for Prolia from FDA

Positive results from Trubion Pharmaceuticals' Phase 2B study of TRU-015 for rheumatoid arthritis

Schering-Plough to present data on boceprevir at the AASLD 2009 Annual Meeting

Genentech reports results of ACTEMRA Phase III study for rheumatoid arthritis

Preclinical data of carfilzomib and PR-957 inhibitors to be presented at 2009 ACR/ARHP meeting

Discovery may yield better understanding of protective gut-dwelling bacteria

Rituxan's sBLA receives a Complete Response from the FDA

Biogen Idec and Biovitrum to conduct rFIXFc clinical trial in hemophilia B patients

PHARMACIA & UPJOHN COMPANY to pay the largest criminal fine ever imposed in the U.S.

Research programme to develop immunological biomarkers for chronic inflammatory diseases

Rituxan drug effective for treating ANCA-associated vasculitis

Abbott announces financial results for the third quarter ended Sept. 30, 2009

National Vaccine Information Center to launch a research fundraising campaign

Decision Resources: Rheumatoid arthritis drug market in India to grow up to $672 million in 2013

Johnson & Johnson announces financial results for the third quarter of 2009

Pharmaceuticals to provide safe needle collection and disposal programs for patients

Nektar Therapeutics presents the results from Phase 2 clinical trial of oral NKTR-118

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Rheumatoid Arthritis News and Research

Latest Rheumatoid Arthritis News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in